PhD (1996) in Pharmacy (Microbiology), Universidade de Lisboa
Post-Doctoral Fellow, Harvard Medical School and Scripps Research Institute, USA
Associate Professor, Microbiology and Immunology, Faculdade de Farmácia, Universidade de LisboaGroup Leader, Molecular Microbiology and Biotechnology at iMed.ULisboa
Program Area Leader, Drug Discovery at iMed.ULisboa
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
J Goncalves interest is on biomolecular and biopharmaceutical engineering aiming the investigation, analysis and integration of genomic and proteomic data towards the design of therapeutic proteins. This will lead us to guide protein engineering through molecular medicine and bio-nanotechnology in a mid- to long-term timeframe. At the center of our biopharmaceutical development we aim at rational antibody engineering as our approach to validate our theoretical concepts. We want to be able to use our hyperstable frameworks for the construction of small domain antibodies in a number of examples, ranging from HIV to cancer and in model domains to a designed catalytic intrabody. The focus on the discovery and development of a new class of therapeutic antibodies and efficient display technologies may allow the rapid identification of binding proteins with high affinity and specificity. We plan to adapt our antibody domain platform to other areas as inhibition of extracellular enzymes and cell surface receptors. Development of better characterization assays and monitoring of antibody therapy in patients, including immunogenicity and pharmacokinetics to biosimilars is current to our work. The evaluation of quality, efficacy and safety attributes of biosimilar antibodies and fusion proteins is at the centre of our clinical collaborations.
Romao S, Simoes S, Moreira JN, Goncalves J. Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies. Scientific Reports 2018; s41598-018-25816-8 (in Press).
Goncalves, Joao et al. Antigenic response to CT-P13 and Remicade in inflammatory bowel disease patients show similar epitope recognition. Alimentary Pharmacology & Therapeutics. 2018, APT_14808 (In press).
Aguiar S, Dias J, Manuel AM, Russo R, Gois PMP, da Silva FA, Goncalves J. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. Adv Protein Chem Struct Biol 2018; 112: 143-182.
Amaral AJ, Andrade J, Foxall RB, Matoso P, Matos AM, Soares RS, Rocha C, Ramos CG, Tendeiro R, Serra-Caetano A, Guerra-Assunção JA, Santa-Marta M, Gonçalves J, Gama-Carvalho M, Sousa AE. miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication. EMBO J. 2017; 36: 346-360
Cunha-Santos C, Figueira TN, Borrego P, Oliveira SS, Rocha C, Couto A, Cantante C, Santos-Costa Q, Azevedo-Pereira JM, Fontes CMGA, Taveira N, Aires-Da-Silva F, Castanho MARB, Veiga AS, Goncalves J. AIDS 2016; 30:1691-1701.